Images List Premium Download Classic

Angioedema

Angioedema-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Therapeutic inhibitory compounds
Lifesci Pharmaceuticals, Inc.
September 14, 2017 - N°20170260163

Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.
(aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use
Bayer Pharma Aktiengesellschaft
August 24, 2017 - N°20170239251

The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired bleeding disorders, wherein ...
Pharmaceutical composition for preventing or treating angioedema, containing extract of peony root or mixture of ...
Korea Institute Of Oriental Medicine
July 27, 2017 - N°20170209510

The present invention relates to a pharmaceutical composition for preventing or treating angioedema, containing as an active ingredient a peony root extract or an extract of a mixture of peony root and licorice. In particular, the extract of a mixture of peony root and licorice according to the present invention inhibits the excessive generation of advanced glycation end products, which ...
Angioedema Patent Pack
Download + patent application PDFs
Angioedema Patent Applications
Download + Angioedema-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Angioedema-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Composition of allergen extracts having reduced toxicity and method of production thereof
Stallergenes
June 08, 2017 - N°20170157240

The present invention concerns pollen allergen extracts, in particular ragweed (ambrosia) pollen allergen extracts, containing reduced amounts of copper-binding-like proteins in order to minimize the risk of toxicity, including induction of angioedema, of those allergen extracts. The invention also relates to methods of preparing pollen allergen extracts containing reduced amounts of copper-binding-like proteins.
Humanized anti-ige antibodies that crosslink cd23 on b lymphocytes but do not sensitize mast cells
Academia Sinica
May 04, 2017 - N°20170121425

A novel humanized anti-ige antibody is disclosed. The antibody is capable of binding to free ige, membrane-bound ige on b lymphocytes, ige bound by cd23, but not to ige bound by high-affinity ige. Fc receptor on mast cells. The present invention relates to the treatment of ige-mediated diseases, including allergic asthma, allergic rhinitis, atopic dermatitis, food allergy, chronic spontaneous (idiopathic) ...
Therapeutic inhibitory compounds
Lifesci Pharmaceuticals, Inc.
February 02, 2017 - N°20170029406

Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.
Angioedema Patent Pack
Download + patent application PDFs
Angioedema Patent Applications
Download + Angioedema-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Angioedema-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Treatment of hereditary angioedema with c1 inhibitor
Santarus, Inc.
December 15, 2016 - N°20160361394

A method for treating acute attacks of hereditary angioedema (hae) whereby a first does and a second dose of a recombinant c1 esterase inhibitor is administered intravenously to the patient, each dose at 50 iu/kg body weight of the patient and wherein the first and second doses are administered within a 24 hour period. The recombinant c1 esterase inhibitor has an ...
Adeno-associated virus mediated delivery of c1ei as a therapy for angioedema
Cornell University
December 01, 2016 - N°20160347822

This invention is directed to a vector which comprises a promoter operably linked to a nucleic acid sequence encoding the human c1 esterase inhibitor or factor xii. The invention is also directed to a composition comprising the vector and a method of using the vector to treat or prevent hereditary angioedema.
Compositions and methods for inhibiting gene expression of factor xii
Arrowhead Madison Inc.
September 22, 2016 - N°20160272978

Rna interference (rnai) triggers for inhibiting the expression of factor xii (f12) gene through the mechanism of rna interference are described. Pharmaceutical compositions comprising one or more f12 rnai triggers together with one or more excipients capable of delivering the rnai trigger(s) to a liver cell in vivo are also described. Delivery of the f12 rnai trigger(s) to ...
Therapy for chronic idiopathic urticaria, anaphylaxis and angioedema
Arrowhead Madison Inc.
September 22, 2016 - N°20160271112

Methods for treating or relieving at least one symptom of urticarial disorders including chronic idiopathic urticaria, angioedema, and anaphylaxis, or a combination of these disorders in a mammal, including humans. The method comprises administering to the mammal a therapeutically effective amount of pramipexole, dexpramipexole or pharmaceutically acceptable salts thereof.
Therapeutic inhibitory compounds
Lifesci Pharmaceuticals, Inc.
July 14, 2016 - N°20160200704

Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.
Methods of treating b2-bradykinin receptor mediated angioedema
Shire Human Genetic Therapies, Inc.
February 04, 2016 - N°20160030416

Methods of treating b2-bradykinin receptor mediated angioedema in a subject by administering a composition containing a 8-(heteroarylmethoxy)quinolone compound, a 8-(arylmethoxy)quinoline compound, or a salt, a stereoisomer, a hydrate, or a solvate thereof. Oral formulations containing a 8-(heteroarylmethoxy)quinolone compound, a 8-(arylmethoxy)quinoline compound, or a salt, a stereoisomer, a hydrate, or a solvate ...
Evaluation and treatment of bradykinin-mediated disorders
Dyax Corp.
December 17, 2015 - N°20150362493

The present disclosure provides methods of evaluating a subject, e. G., a subject at risk for or suffering from a pkal-mediated or bradykinin-mediated disorder, based on values (e. G., percentages) of intact and/or cleaved kininogen in a sample of the subject. Provided methods permit analysis of patients with plasma kallikrein-mediated angioedema (kma), or other diseases mediated by pkal useful ...
Angioedema Patent Pack
Download + patent application PDFs
Angioedema Patent Applications
Download + Angioedema-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Angioedema-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Pharmaceutical composition and functional food comprising natural extracts for preventing or treating diabetic complications or ...
Korea Institute Of Oriental Medicine
December 03, 2015 - N°20150343005

The present invention relates to a pharmaceutical composition and a health functional food composition for prevention, treatment or amelioration of diabetic complications or angioedema containing a mixed extract of hedera helix leaves and coptis chinensis as an active ingredient. More specifically, the present invention relates to a pharmaceutical composition and a health functional food composition for prevention, treatment or amelioration ...
(aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use
Bayer Pharma Aktiengesellschaft
May 07, 2015 - N°20150126449

The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired bleeding disorders, wherein ...
Methods for modulating factor 12 expression
Bayer Pharma Aktiengesellschaft
August 14, 2014 - N°20140228300

Disclosed herein are methods for decreasing factor 12 and treating or preventing inflammatory conditions in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to factor 12 include hereditary angioedema (hae). Methods for inhibiting factor 12 can also be used as a prophylactic treatment to prevent individuals at risk for developing an ...
Methods for modulating kallikrein (klkb1) expression
Bayer Pharma Aktiengesellschaft
July 31, 2014 - N°20140213631

Disclosed herein are methods for decreasing kallikrein and treating or preventing inflammatory conditions in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to kallikrein include hereditary angioedema (hae). Methods for inhibiting kallikrein can also be used as a prophylactic treatment to prevent individuals at risk for developing an ...
Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, ...
Bayer Pharma Aktiengesellschaft
July 31, 2014 - N°20140213505

Provided herein are peptide inhibitors of the interaction between end binding protein 3 (eb3) and inositol 1,4,5-trisphosphate receptor type 3 (ip3r3). Also provided are methods and materials for treating lung injury, including acute lung injury, which may include hyperpermeability of lung vessels, vascular leakage, the development of edema, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion.
Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, ...
Bayer Pharma Aktiengesellschaft
June 05, 2014 - N°20140155314

Provided herein are peptide inhibitors of the interaction between end binding protein 3 (eb3) and inositol 1,4,5-trisphosphate receptor type 3 (ip3r3). Also provided are methods and materials for treating lung injury, including acute lung injury, which may include hyperpermeability of lung vessels, vascular leakage, the development of edema, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion.
Diagnosis and treatment of angioedema
Bayer Pharma Aktiengesellschaft
February 20, 2014 - N°20140051099

The present patent application relates to a method for diagnosing angioedema with a gain-of-function mutation of kinin formation, and for determining the amount of bk or des-arg9 -bk antagonist required for halting the effects of angioedema, from a plasma sample of a patient. The invention also relates to a kit for said determination.
Loading